Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
QBL Half-Year Report; Milestones, Finances and More. Will this be the turningpoint for QBL 2018 ? MUST READ.
https://www.asx.com.au/asxpdf/20180319/pdf/43sjwqc8zzw0fv.pdf
QBL now on FACEBOOK interactive webpage very helpfull !
See QBL-board for my personal reflections and news of the company.
This is a special story - Worth the time to find out and possibly invest.
For my own part I have made a re-fill, since they are low sharevalue today.
I reckon to diversify investments in this sector a good strategy - regulations and laws are changing and Australia has open up a lot now.
In my opinion this stock is very undervalued compared to peers with the same/similar growing value from various streams of Revenue and CASH !
MMJ stocks in general have a great future ahead, off course one have to examine each play properly - there is stocks/companies who will fall.
I thought it should be intresting to compare different MMJ stocks - on a international level. Some are not yet listed, some are pennystocks and others are quite high value on the stock market.
The trend off M&A, buyouts and consolidation will continue, new collaborations and JV will emerge along the way. USA, Canada, Israel and Australia to mention some, is markets who grow rapidly.
What has become intresting is to see what will happen with the gigantic Asian market ? Who will get a foothold there and can take advantage of a "first mover" situation ?
I reckon a tiny Company like QBL with its 3 divisions today, has a fair shot to take some percentage of this massive market. Take a look at the QBL-board, see HALF-YEAR report (came out 2 Days ago) and enjoy, good luck.
Doctors get quicker approval of medical marijuana prescriptions under a streamlined process announced by the NSW and federal governments.
https://www.sbs.com.au/news/nsw-improves-medicinal-cannabis-access
Take a look at this stock, QBL, it`s absolutely worth it.
See the QBL-board for more info, website and also a new FACEBOOK webpage.
A excellent choice to DIVERSIFY MMJ-investments and high reward potential.
HALF-YEAR REPORT came out 2 Days ago; very good sum up on QBL 2017.
(See link on QBL-BOARD)
Considering this is a new industry, it`s difficult to get all information when doing due dilligence - still, the QBL story strikes me as a US-pot stock in 2014... explosive potential. We can see a 500% gain within 5 weeks time, nov-dec 2017.
Still, I reckon this is just the beginning - today it`s trading around 5 cent, dirt cheap ! I urge you to read a sum-up, to get the larger picture. I think this one has so much to offer and I`m in it for the long run. Good luck.
The Truth About Medical Cannabis
18 999
Cannabis Club Australia
Publiced 9 april 2017
See QBL Half-Year Report, came out 2 Days ago, it`s really good sum up !
This piece came out 1 year ago and was recorded before that - a lot has progressed since then; still there is a lot to be done in educate people.
QBL North American MMJ chemists world first in the Medical Cannabis industry togheter with Israels only Cannabis database with leader of MMJ science work. QBL recently signed a 3-year contract with "Dr MMJ" (see QBL- board "Autoimmune Disease")
MCL with its contacts and knowledge in the Australian Cannabis regulatory environment, together with its uniquely cultivated and exclusive seed bank, is anticipated to be of immense benefit to the continued research of its intended JV partner in the newly developed pill and other medications that will be studied by the combined group in order now to start produce.
(Today came Half-Year report; Milestones and much More ! )
The combination of North-America, Israel, Australia and Canada collaboration will benefit all parts in this highly professional new Group. With there various skillsets, resources and experience, QBL has managed to involve very strong partners to this joint venture.
(QBL-board and Facebook webpage more info)
QBL MMJ Half-Year Report; Milestones, Finances and More. Will this be the turningpoint for QBL 2018 ?
https://www.asx.com.au/asxpdf/20180319/pdf/43sjwqc8zzw0fv.pdf
(See board, website and Facebook webpage on more information)
World First for MMJ;MCL, Canada in Autoimmune Disease Research.Feb 26, 2018 - (ABN Newswire) MCL subsidiary of QBL.
Another dot connecting... all the parts getting togheter in success.
SUMMARY at the bottom part of the news. Important; The "BIG LETTER" part, "Highlights" and "WORTH SEE"
http://www.4-traders.com/QUEENSLAND-BAUXITE-LTD-11939085/news/Queensland-Bauxite-Ltd-ASX-QBL-A-World-First-for-MCL-in-Autoimmune-Disease-Research-26053610/
The Board of Queensland Bauxite Limited (ASX:QBL) is pleased to announce that its subsidiary company Medical Cannabis Limited (MCL) through its wholly owned subsidiary Medical Cannabis Research Group Pty Ltd (MCRG), has signed a Research Funding Agreement with the Research & Development Foundation at the Technion Institute, Haifa, Israel. The agreement revolves around the research of Prof. David (Dedi) Meiri, from the Faculty of Biology at the Technion Institute.
Cannabis as a Potential Therapy for Multiple Sclerosis
According to the agreement MCRG will sponsor the continued Research of how the cannabis plant can be used for the treatment of Multiple Sclerosis (MS). Prof. Meiri has identified the synergistic relationship between the Cannabis plant and the human genome that will form the basis for this research.
Highlights
- Medical Cannabis Ltd (MCL) a subsidiary of Queensland Bauxite Limited (ASX:QBL), completes an arrangement to sponsor research into medical cannabis treatments for Multiple Sclerosis (MS).
- MCL through its Medical Cannabis Research Group Pty Ltd (MCRG) has signed an agreement with the Technion Research & Development Foundation for the performance of research by Prof. David (Dedi) Meiri, from the Faculty of Biology at the Technion - Israel Institute of Technology in Haifa, Israel. Prof. Meiri is Head of the Technion's Cannabis research team. According to the agreement, MCRG will sponsor research into how the cannabis plant can be used in the treatment of symptoms and halting the progression of autoimmune diseases with special emphasis on Multiple Sclerosis (MS).
- Long-standing and approved MS treatments can reduce relapses, but current solutions may slow down, but ultimately do not arrest the progression of the disease.
- The overall objective of Prof. Meiri's study is to identify specific cannabis compounds that can be used in clinical trials as a potential treatment for Multiple Sclerosis (MS).
- MCL through its Medical Cannabis Research Group (MCRG) will agree to fund Research into Prof. Meiri's study in return for an exclusive license for any product derived from the Research.
- Should a successful product eventuate, the Board believes, in time, this Research has the potential to be a global medical 'game changer' for MS sufferers, and a material revenue stream for MCL.
- MCRG has committed to fund USD$3M over a 3-year period, towards the research budget, in return for an exclusive license of any product to be developed from this research for MS, or potentially for any product that could alleviate or treat any other auto immune disease that could be developed from this research.
Pnina Feldman, Executive Chairperson of QBL says: "The Boards of QBL and MCL feel privileged to be working with Prof. Meiri and his team of medical cannabis researchers at the Technion-Israel Institute of Technology, not only for the opportunity to be in with top researchers who are one of the leaders in the world with this research, and not only to commercialise the products that may result from this research, but for this unique and ground-breaking opportunity to work diligently towards the betterment of health worldwide.
Everyone knows someone with an- autoimmune disease in one form or another, and there could be no more satisfying outcome, or more important work, than making the lives of these people not only easier, but hopefully enabling respite from symptoms and cures for disease. The benefits of the age-old cannabis plant, combined with state of the art medical technology, is opening new horizons, and we are both proud and humbled to be amongst the pioneers supporting and being a part of this amazing research."
Assistant Professor, Heads the "Laboratory of Cancer Biology and Cannabinoid Research", Technion, Israel Institute of Technology, Israel.
David (Dedi) Meiri, PhD, is an Assistant Professor at the Faculty of Biology at the Technion Israel Institute of Technology and a member of the Technion Integrated Cancer Center (TICC). Dr. Meiri's scientific background is highly diverse. He holds a M.Sc. in biochemistry and a Ph.D. in plant biotechnology from Tel Aviv University. Dr. Meiri conducted his post-doctoral fellowship at the Ontario Cancer Institute where he expanded his knowledge in human biology and cancer pathogenesis and focused on the role of the GEF-H1 protein in tumor invasion and metastasis. Upon completion of his post-doctoral fellowship, Dr. Meiri took a position at the Technion Israel Institute of Technology, where he heads the "Laboratory of Cancer Biology and Cannabinoid Research".
Presently, his lab investigates the therapeutic potential of phytocannabinoids, the unique active compounds of the Cannabis sativa plant. On top of other research being conducted in the lab, the main focus of his research is to determine the antitumor effects of cannabinoids, including the anti-metastatic and pro-apoptotic effects of phytocannabinoids.
From the establishment of his lab it has grown significantly and it is now comprised of 38 scientists; a highly trained team of skilled plant biologists, chemists, cancer experts and neuroscientists who work together in synergy to complement one another in order to achieve the highest level of results.
Dr. Meiri's lab, is one of the leading laboratories in the world that is exceptionally equipped with the capabilities and resources to ask and answer almost any question in the field of medical cannabis.
Dr. Meiri operates the "Cannabis Database Project" and his lab is currently involved in eight clinical trials covering diverse aspects of cannabis treatment, such as: colon disease, pain prevention, cancer treatment and epilepsy. He collaborates with cannabis growers, clinicians and major manufacturers and distributors of medical cannabis, including Andrew Kavasilas from QBL: MCL in the purpose of revolutionizing cannabis treatment.
Dr. Meiri is also highly involved in governmental regulations and is a residing member in several Israeli Ministry of Health committees which seek to advance the fundamental understanding of optimal cannabis usage and minimization of adverse side effects.
Background - Technion Israel Institute of Technology
Technion - Israel Institute of Technology was founded in 1912 in Haifa and is the oldest university in IsraelThe Institute is currently rated #93 in the World's Top 500 Universities and is the only Israeli university in the top 100 of the list. (2017 - Shanghai Ranking World Leading Universities)
Technion researchers, including three Nobel laureates in chemistry, have won many International awards for their research in the fields of Microbiology, Microbial Diagnostics, Genomics, Antibiotics to name just a few. Technion people, ideas and inventions make immeasurable contributions to the world including life-saving medicine, sustainable energy, computer science, water conservation and nanotechnology.
Technion is widely recognized as a global leader in Medical Cannabis Research. Israel has been leading the world since the early 1960's in Medical Cannabis research.
In November 2017, Times Higher Education ranked Technion as the world's leading academic institution in teaching digital skills to students, ahead of the prestigious American M.I.T. University.
(WORTH TO SEE !)
Background - Autoimmune disease
The Australian Society of Clinical Immunology and Allergy (ASCIA) states that autoimmune diseases affect around 5% of people and are one of the most important health issues in Australia and New Zealand.
An autoimmune disease is a disease in which the body's immune system attacks healthy cells. The most common types of autoimmune diseases include:
- Rheumatoid Arthritis: A chronic inflammatory disorder affecting many joints, including those in the hands and feet.
- Lupus: An inflammatory disease caused when the immune system attacks its own tissues.
- Celiac Disease: An immune reaction to eating gluten, a protein found in wheat, barley and rye.
- Multiple Sclerosis: A disease in which the immune system eats away at the protective covering of nerves. This condition can last for years or be lifelong. In MS resulting nerve damage disrupts communication between the brain and the body.
- Type 1 Diabetes: A chronic condition in which the pancreas produces little or no insulin.
- Other diseases include: Sjogren's syndrome, Polymyalgia rheumatica, Ankylosing spondylitis, Alopecia areata, Vasculitis, Temporal arteritis, Crohn's disease, Graves disease (thyroid) etc. In all, there are 80 known autoimmune diseases, with an estimated 50 million Americans suffering these diseases in increasing numbers.
The disorders range in severity from mild to disabling, depending on which system of the body is under attack and to what degree.
The causes of autoimmune diseases are unknown. In many cases it appears that there is some hereditary tendency. However, other factors such as injections and some drugs may play a role in triggering autoimmune diseases.
No Known Cure
Autoimmune disorders in general have no known cure, but the conditions can be somewhat controlled and managed in many cases.
Treatments
Historically, treatments include:
- Anti-inflammatory drugs - to reduce inflammation and pain.
- Corticosteroids - to reduce inflammation. They are sometimes used to treat an acute flare of symptoms.
- Pain-killing medication - such as paracetamol and codeine.
- Immunosuppressant drugs - to inhibit the activity of the immune system.
- Physical therapy - to encourage mobility.
- Treatment for deficiency - for example insulin injections in the case of diabetes.
- Surgery - for example to treat bowel blockage in the case of crohn's disease.
- High dose immunosuppressants - the use of immune system suppressing drugs (in the doses needed to treat cancer or to prevent the rejection of transplanted organs), have been tried recently, with promising results. Particularly when intervention is early, the chance of a cure with some of these conditions seems possible.
- Stem cell Research - Recent experimentation in Israel with stem cell implanting to treat impaired bodily functions is being trialled and although very invasive is showing some progress.
The goal of the cannabis research in the field of auto immune disease is to find a treatment and possible cure that does not have the serious side effects of other treatments being researched or used to date.
The Role of Cannabis in Autoimmune Diseases
So far, the approved and available treatment for autoimmune diseases with medicinal cannabis, has been in the area of pain relief, the cannabis formula replacing morphine and its derivatives, with morphine in high and frequent doses being serviceable mainly in palliative care. The medicinal cannabis pain relief available for (MS) for example, is most effective in relieving pain, enabling sufferers to function better without the side effects of pain relieving drugs such as morphine. The danger of morphine has been recognized by the Australian authorities, who as of February 1, 2018 requires codeine to be a prescription only drug.
Andrew Kavasilas, Technical Director of MCL, said: "This is a very logical avenue of research, especially when the only semi-legal Cannabis medicine in the world was developed for the treatment of MS. That was a first wave cannabinoid medicine and a vast amount of knowledge has been gained since then. There's an incredible amount of work being done in Israel which has capitalised on many opportunities due to their government's willingness to allow medical Cannabis use by well over 100 000 people, while the profession scientific research catches up to break down all this valuable evidence".
Dr David (Dedi) Meiri - Cannabis as a Potential Therapy for Multiple Sclerosis
Due to the legal access to medical researchers and doctors of high and low THC Cannabis plants under the auspices of the Israeli Health Department, Israel is currently at the forefront of medicinal cannabis research, and the world-renowned Dr Meiri is arguably today's leading medicinal cannabis researcher in Israel, if not in the world.
Dr Meiri is head of the Technion's Cannabis Research team and will be the principal investigator in research to be funded by MCRG (the research and wholly owned subsidiary company of MCL). Dr Meiri lectures and teaches about the latest developments in cannabis research throughout the world, and has recently been on a lecture tour to Australia, speaking in Sydney at a function organized at Wolper hospital for doctors interested in Dr Meiri's new and exciting research insights.
Assisting Dr Meiri's team of close to 30 researchers, will be supporting investigators Dr Igal Louria-Hayon PhD and Dr Gil Lewitus PhD.
Overall Objective
The overall objective of Dr Meiri's study is to match effective cannabis extracts and specific cannabinoids composition that regulate/modulate immune function, specifically, autoimmunity in MS in order to optimize treatment for MS patients.
It is hoped that achieving a successful outcome of the overall objective could lead to a possible cure for MS through the strengthening of the immune system, which in turn will assist the research into other auto immune diseases and diseases in general.
Dr Meiri Comments:
"Although current treatment of MS with broad-spectrum immunomodulatory drugs reduces immune cell activity and entry into the central nervous system (CNS) and decreases relapse frequency, they are often associated with side effects, ranging from flu-like symptoms to the development of other auto-immune disorders; fatal opportunistic infections such as progressive multifocal leukoencephalopathy; and other malignancies.
"These side effects highlight the need to identify more specific therapeutic targets that can be effectively modulated without inducing such adverse reactions. In addition, it is increasingly acknowledged that although the long-standing and approved MS treatments can reduce relapses, they do not ultimately halt the disease. Therefore, neuroaxonal damage, which results in progressive physical disability, continues to accumulate and becomes permanent throughout the disease progression.
"Recently, the therapeutic potential of phytocannabinoids, the unique active compounds of the cannabis plant, has been discovered in the area of immunology; More than 140 phytocannabinoids have been identified within the cannabis plant. A few specific natural and synthetic cannabinoids have been proposed to have therapeutic potential for various diseases. The U.S. Food and Drug Administration (FDA) recently approved the use of several synthetic cannabinoids to be available by prescription for pain relief treatment.
"Cannabinoids have been largely characterized for their action in the immune system and were tested in several in vitro and in vivo disease models for inflammation (a common symptom of numerous autoimmune diseases).
Recent research showed that administration of tetrahydrocannabinol (THC) with mice triggered significant caspase medicated cell death in T cells and dendritic cells, resulting in immunosuppression. In addition, other research demonstrated that cannabinoids downregulate cytokine and chemokine production and at times upregulate T regulatory cells as a mechanism to suppress inflammatory responses. The targeted actions of cannabinoids in the endocannabinoid system is also involved in immunoregulation.
"CDB another abundant cannabinoid was found to exhibit a suppressive effect on T cell functional activities via reducing IL-17 cytokine secretion, a key autoimmune factor which was also shown to be involved in multiple sclerosis (MS). In this context, its additional neuroprotective effects, which included the upregulated of a number of anti-oxidative genes (e.g. those of glutathione synthesis) in CBD exposed microglial cells from inflammation-induced apoptosis may significantly enhance its anti-inflammatory beneficial properties and account for alleviation of MS pathology.
"As of now, there are several different cannabinoid medications approved for patients with MS, inducing cannabis in its natural form. Cannabis is primarily used to reduce muscle stiffness and pain. However chemical trials to date done with specific cannabinoids showed small or no effect on disease progression from the above current cannabinoid medications.
"Other compounds in Cannabis have been poorly studied regarding their potential immunosuppressive effects. For example, it has been shown that terpenoids are key components of cannabis activity as they are known to participate in making the plant extract more potent than synthetic cannabinoids. Overall, Cannabis's multiple inflammatory effects on various immune cell types, together with the vast number of phytocannabinoids and different ratios of cannabinoids in different strains makes the Cannabis plant a complex matrix with great therapeutic potential.
"Cannabis chemical composition analyses currently focus on identifying and qualifying and quantifying several major Cannabinoid types including THC, CBD, and in some recent studies also cannabichromene (CBC), cannabinol (CBN), and cannaligerol (CBG). Other Cannabis compounds which may be important for their therapeutic effects, have predominantly been neglected.
"In order to identify more cannabinoid types, we developed, in our lab, a novel ability to analyze the metabolomics and the specific chemical composition of cannabis plants.
"As far as we know, 'WE ARE THE ONLY LAB IN THE WORLD TODAY THAT HAVE THESE ABILITIES OF COMPREHESIVELY PROFILING THE CANNABINOID COMPOSITION FOR A VARIETY OF CANNABIS STRAINS AND ALSO TO BE ABLE TO PURIFY SINGLE PHYTO-CANNABINOIDS AND CREATE "SUSPECT PROFILES" FOR EXAMINATION IN DIFFERENT TYPES OF STUDIES.'
Research Plan
"In the last year, we established the novel ability to analyze the metabolomics and the specific chemical composition of Cannabis plants (principally of phytocannabinoids and terpenes). We intend to identify the effects of different cannabinoids and terpenes both individually and in combination on the function of immune cells, specifically on MS-derived autoimmune and regulatory cells in vitro. We intend to evaluate the immunomodulatory properties of specific cannabinoid extracts in in vivo rodent models of MS. This will enable us to detect the most effective extracts in in vivo rodent models of MS. This will enable us to detect the most effective Cannabis extract and cannabinoid profiles for regulating immunopathology in MS.
Specific Aims
- Characterize clinically-used Cannabis strains using comprehensive mass-spectrometry based metabolomics.
- Screen for the immunoregulatory properties of different Cannabis extracts on immune cell function and MS immunopathology.
- Demonstrate the immunomodulatory properties of specific Cannabis extracts on various MS rodent models and identify specific compounds that can then be used in clinical trials as potential treatment for MS.
Significance
"Affecting millions of people worldwide, Multiple Sclerosis (MS) is the most common autoimmune disorder affecting the central nervous system. Therapies for MS are only partially effective and there is no known cure. Therefore, there exists a great and unmet clinical need for the development of neuroprotective treatments. Today, MS patients are treated with medical Cannabis primarily for the palliative purposes. Furthermore, the specific Cannabis strain for palliative treatment is chosen arbitrarily. Consequently, evaluating the immunomodulatory properties of Cannabis in MS and tailoring the best combination of phytocannabinoids may open new treatment possibilities for MS patients with the intention of finding a cure."
Summary
"In this work we aim to elucidate the immunoregulatory properties of phytocannabinoids and terpines in MS, as well as further investigate Cannabis's mechanisms of action in these areas. This research not only has the ability to advance the identification of new drug candidates, but also advance our abilities to optimize Cannabis treatment options and efforts towards the creation of personalized medicine for MS patients."
Pnina Feldman, Executive Chairperson and Director of Business Development of QBL stated: "Having had the pleasure of meeting Dr David Meiri at the Wolper Doctors Conference, in Australia, in June 2017, I was very happy for the opportunity to open a dialogue with Dr Meiri, which was the beginning of this current deal. We are very excited about the work being carried out by Dr Meiri, and his team at Technion, and we believe that this research will hopefully be of major benefit worldwide, and in particular to QBL shareholders who support our ground-breaking work."
To view figures, please visit:
http://abnnewswire.net/lnk/4V8V11WC
About Queensland Bauxite Ltd:
Queensland Bauxite Limited (ASX:QBL) is an Australian listed company focused on the exploration and development of its bauxite tenements in Queensland and New South Wales. The Company's lead project is the South Johnstone Bauxite Deposit in northern Queensland which has rail running through the project area and is approximately 15-24 kilometres from the nearest deep water port. The Company intends to become a bauxite producer with a focus on commencing production at South Johnstone as early as possible. The Company also pursues additional investment opportunities, and has acquired a 55% shareholding in Medical Cannabis Limited, an Australian leader in the hemp and Cannabis industries.
Contact:
Queensland Bauxite Ltd
Tel: +61-2-9291-9000
For further information or any queries please email the Company at:
sfeldman@queenslandbauxite.com.au
Copyright (C) 2018 ABN Newswire. All rights reserved., source Press Releases English
$ACG.C - Alliance Growers to Build Greenhouses at Botany Center
http://tsxpennystocks.ca/marijuana/news/585-alliance-growers-to-build-greenhouses-at-botany-center
$SVSN Cannabis Clinic Jan-17, 2018 NOW OPEN
Please look at the . THREE . YEAR . CHART . ! ! !
StereoVision has been a Stealth Success Story
https://www.otcmarkets.com/stock/SVSN/news/CannaVision-Announces-February-1-Grand-Opening-of-Their-Bay-Pines-Medical-Cannabis--amp--Holistic-Pain-Management-Clinic-in-St--Petersburg--Florida?id=180636&b=y
Until2017
New medical cannabis play with great potential - now the best opportunity in a very attractive stock, compared to peers. Study the webpage with it`s clearifying information - they have made a good job at presenting the story.
The question about the company name will be explained and QBL business has 2 bransches today; mining bauxite and recently (march 2017) invest in a very intresting canadian cannabis and hemp JV with a experienced partner.
Watching the 2 guys from both businesses, gives me a good feeling of a success JV took place. The flexibility of catching the moment... and the experience - the interview is special (see webpage) !
If you look for early days cannabis/hemp and great ROI potential - this company is a strong candidate. Since it`s a collaboration, I reckon it`s a strength there is double knowledge in different questions, when working togheter for the common goal of the companies best interest.
.
Many good MJ tickers to play. 2018 is changing everything
MJ READ:
SLEEKSCAPE’S 2018 MARIJUANA MANIA THESIS
THE MECHANISTICS OF A MANIA
The cryptocurrency craze. The Nasdaq internet sector supernova. Cabbage Patch Kids. Elvis.
Manias are periods of time marked by outlandishly gargantuan growth spurts in the perceived value of a bitcoin, a stock, a doll, a rockstar. They are captivating to observe and thrilling to experience. This is where boredom goes to die. Dopamine.
In the stock market world, manias tend to occur most frequently in novel and revolutionary industries possessing the potential for gigantic growth rates, stratospheric ceilings and global dissemination.
An equity sector mania is marked by a tremendous surge in buying interest coupled with an unusually low selling interest. Demand overwhelms supply and stock prices escalate rapidly as many investors recognize the potential for enormous returns, and as a result, hold for far bigger profits than usual. This “strong hands” mentality serves to further decrease the freely tradable shares or “float” of a stock and amplifies the strength of the upward movement in price. As the demand for shares continues to increase over time with rising numbers of incoming investors, the concomitant dwindling of the available supply serves to significantly heighten the value of the stock. In such an environment, sentiment becomes the primary driver of stock price as traditional valuation metrics like market capitalization are rendered essentially irrelevant. In a true cannabis mania, returns of several thousand percent are readily achievable if one owns the right portfolio of stocks.
The OTC marijuana sector is certainly no stranger to manias, which seem to have a predilection for even calendar years – 2014 and 2016 representing the two most recent occurrences.
The marijuana sector mania cycle resembles a hybrid of the euphoric elevator ride and deflating crash of the 1999-2000 internet stock bubble mixed with the cycling nature of a catalyst-driven craze with an uncertain future like bitcoin.
THE 12 STAGES OF THE MJ SECTOR MANIA CYCLE
Manic Mania
Strong Mania
Mediocre Mania
Hot
Warm
Lukewarm
Cool – CURRENT STAGE
Cold
Icy
Colorado Bear
Canada Bear
Polar Bear
Here is the cycle broken down into its four main constituents:
MANIA
Manic Mania
Strong Mania
Mediocre Mania
PREMANIA
Hot
Warm
Lukewarm
DEFROSTING
Cool
Cold
Icy
FROZEN
Colorado Bear
Canada Bear
Polar Bear
2014, 2015, 2016, 2017: A TEXTBOOK ILLUSTRATION OF THE CATALYST-BASED MANIC CYCLING NATURE OF THE OTC MARIJUANA SECTOR
2014/2015
Anybody who witnessed the 2014 MJ MANIA will never forget it. A stock gaining 75000% in just 10 weeks is a story worthy of satire and science fiction. But it actually happened. I watched it. SPLI did move from .0006 to .45 in 70 days.
Colorado initiated sales of recreational marijuana in dispensaries on January 1st and the media fell in love with the story. CNBC, CNN, FOX NEWS, MSNBC, CBS, NBC, ABC. The New York Times, The Los Angeles Times, The Chicago Tribune. Local rags from the Denver Gazette to Youtube channels in Bangladesh. The world’s media covers a truly historic moment like a gigantic tarp. The internet. Radio. Print. Television. Podcasts. In workplace cafeterias and cubicles. In Gymnasiums and Barbershops. On college campuses. On ski lifts. On Pluto. Everywhere you turned, somebody was talking about legalized pot in Colorado.
What began as a polygonal news story about Colorado as the ultimate marijuana trailblazing state in America -- with all of its socioeconomic, political, and historical dimensions -- quickly transitioned into a tale about the rapidly escalating marijuana stocks and ever-growing numbers of newly minted penny stock millionaires. It was a double marijuana mania. The economic sector and the stock sector. With omnipresent media attention focused on both stories.
The party lasted almost 3 months. And then the SEC halted PHOT, the leading symbol of the marijuana stock uprising and the most heavily traded ticker in the universe of pot stocks. And then a second halt. And a few more for good measure. The mania had ended. A single catalyst had sparked the mania and now it was extinguished. With a complete absence of mania-worthy future catalysts, the rest of 2014 was a bloodbath and the entirety of 2015 was a mere continuation on continually decreasing trading volumes.
The pattern of manic cycling with an even year/odd year alternation in the cannabis sector was cast.
2016/2017
The year 2016 held a lot of promise. The severe depression in MJ stocks for nearly two years led to a marked decline in stock prices, with the large scale money outflow draining the sky high valuations to more investable levels. Many even described the MJ stocks as undervalued and cheap.
The main factor in common to both 2014 and 2016 was a bona fide catalyst.
The November 2016 election was shaping up to have a tsunami of states on the ballot.
And not just four medical states, but five states for recreational cannabis, including both coasts. The largest state in the union and the first northeast metropolis state -- California and Massachusetts – along with Nevada, Arizona and Maine. This was huge.
And to make things even more bullish, Hillary Clinton was heavily favored to defeat Donald Trump and the democratic party platform contained the recommendation to change marijuana’s federally illegal Schedule I status to Schedule II, essentially a de facto proclamation of federal legalization of medical marijuana.
The ramification of such a rescheduling would be profound as banks would finally be able to work with the marijuana industry. Corporate marijuana was about to arrive. And financial institutions would be able to provide traditional financing to marijuana companies, opening the floodgates to mammoth growth in the private sector. Marijuana companies would become investment-worthy and be trading on the Nasdaq/NYSE within the next 18-24 months with federal legalization by 2020. It felt like all the stars were aligned for MJ mania to grip the sector once again.
And sure enough, the sector begun to turn around in early 2016. By March, it was obvious that serious money flow into marijuana stocks had returned and the 4/20 effect was back.
The stocks then experienced their typical summer doldrums, compounded by the DEA’s decision to keep cannabis listed as a Schedule I substance.
But on the first market day after Labor Day, the sector roared back to life, THE 2016 ELECTION GRAND SALAMI was born and the first bona fide mania since 2014 was sparked. It was BOOM TIME. Over the next two months leading up to Election Day on November 8th, the media covered the ramifications of this election for the American marijuana legalization movement. With telephone polls in California, Massachusetts and Nevada indicating big wins for recreational marijuana legalization, the cannabis stocks skyrocketed. Clinton remained heavily favored and expectations were a continuance of the Obama era policy since 2013, marked by the Cole memo, which permitted states to be laboratories of democracy for marijuana legalization without federal interference so long as certain conditions were followed, essentially erasing any fear of a federal government crackdown.
The outcome of the 2016 presidential election was a huge upset. The polls were dead wrong and Trump emerged victorious, bringing several unexpected ramifications for the cannabis sector.
There were two major reasons why The Trump victory caused the end of the 2016 MJ Mania.
The first is obvious -- Trump’s position on rescheduling marijuana was nebulous at best, and two of the most ardent and nationally well-recognized cannabis prohibitionists, Jeff Sessions and Chris Christie, were heavily favored to be appointed to positions in his cabinet. This naturally led to fears that a federal crackdown on marijuana and a reversal of the Cole memo was quite possible.
The second was more subtle but just as damaging.
The outsider underdog candidate taking down the Clinton political machine was such an enormously historical political event that it swallowed up media coverage about all other Election Day results. Nobody was talking about the marijuana revolution anymore. The media’s attention on marijuana turned off so quickly, it almost felt like California, Massachusetts, Nevada and Maine had actually voted against adult use legalization. The media was 100% Trump, 24 hours a day. Without any positive media attention to bring new investors into marijuana stocks, fear of the unknown and a potential federal crackdown took hold.
So instead of the election serving as a catalyst for marijuana going mainstream, things seemed to be frozen in time, or even worse, potentially moving backward. The marijuana sector consequently tanked and the general sentiment shifted from euphoria to a mix of anxiety and deflation.
While many investors left the marijuana sector after the election, the dip created by the massive selloff in November was stabilized in December by investors who hoped the silence on the issue of marijuana legalization meant that Trump’s pro-entrepreneurialism and support of free enterprise would extend to the burgeoning American cannabis economy.
In early 2017, with continued silence from the incoming administration on marijuana policy, the sector started to warm up again and a reawakening of the 2016 election mania seemed like a distinct possibility. In late February, Sean Spicer and Jeff Sessions both made threatening comments about the possibility of a federal crackdown on marijuana, which quickly dampened sentiment. During the remainder of 2017, with no significant positive catalysts on the horizon, the marijuana sector collapsed under the fear of government interference.
The fundamental lesson of 2013-2017 is clear: The development of a mania based only on a single catalyst, in the absence of any additional near-term positive catalysts, is vulnerable to disruption by a significant negative disturbance.
THE 2018 MARIJUANA MANIA
2014 BOOM… 2015 BUST… 2016 BOOM… 2017 BUST
So many are now saying the pattern is set for 2018 to be BOOM
And sure, patterns certainly possess predictive value but we have a lot more going on in 2018 than just the latest data point in a sequence.
The sociocultural climate has undergone a significant transformation in a relatively brief period of time. Just a decade ago, the dominant winning arguments against recreational legalization were concerns about adolescent usage, the gateway theory and remnants of reefer madness. Now the winning arguments are in support of ending the marijuana prohibition. In the past few years, social justice issues have moved to the forefront amid concerns about the targeting of certain minority populations, namely African Americans and Latinos, who are arrested for possession of marijuana at a much higher rate than Caucasians, even though usage rates are nearly identical. Economic arguments have also swelled in popularity with renewed focus on regulating and taxing cannabis instead of continuing to waste government funds fighting a losing war. For the first time in the history of the well-regarded Gallup poll, Republicans favoring legalization have reached a majority of 51%, an increase of 9 points in just the last year alone. In the same poll, 64% of Americans overall favored legalization.
Support for medical marijuana legalization has been polling consistently above 80% and in the latest Quinnipiac poll, an overwhelming 94% of respondents believed in the cause.
The geopolitical landscape has shifted dramatically as well, particularly in the Western Hemisphere where Mexico, Puerto Rico, Chile and Colombia have legalized medical marijuana.
Uruguay has already legalized recreational cannabis and Canada is on track to do so in the summer of 2018.
In the United States, the entire plant is now fully legal for medical purposes in 29 states, and for recreational in the District of Columbia and the following 8 states – Colorado, Washington, Oregon, California, Massachusetts, Alaska, Nevada and Maine.
Marijuana has some serious momentum in America these days.
MARIJUANA STOCKS: A CATALYST DRIVEN SECTOR
The most logical way of thinking about the cycling movement of the marijuana sector from 2014-2017 is that it is driven by catalysts.
Positive catalysts cause the eruption of manias, which can start immediately after an event or 1-2 months beforehand.
Colorado starting recreational cannabis sales in January 2014 and California/ Massachusetts/Nevada voting for recreational legalization in November 2016 are the textbook examples.
Negative catalysts end manias and start depressions, as occurred in March 2014 with the SEC halting several pot stocks, in November 2016 with Trump’s election victory increasing the likelihood of fierce prohibitionists Sessions and Christie becoming cabinet members, and in February 2017 with the Sessions/Spicer comments signaling the possibility of a federal crackdown on recreational marijuana.
Once a negative catalyst has caused a depression, the absence of any future positive catalysts ensures the depression will continue.
By the same token, positive catalysts are required to end depressions.
The last two bear markets lasted from March 2014 - February 2016 and from February 2017 - November 2017, only ending due to the 4/20/16 and 1/1/18 (CA recreational sales) catalysts, respectively.
So the idea that manias in the marijuana sector cannot last longer than 2-3 months is not supported by thoughtful analysis. With a sample size of only two manias, both ended by negative catalysts, it is more logical to conclude that negative catalysts have the power to end manias triggered by a single catalyst; otherwise, it is likely both manias would have continued for longer periods of time.
It is quite clear that the marijuana sector does not cycle randomly but due to the impact of positive catalysts, negative catalysts and longer periods with no catalysts at all.
THE CHARACTERISTICS OF CATALYSTS
Amplitude:
Positive or Negative
Duration of Effect on MJ sector:
Short: Days to Weeks
Medium: 1-2 Months
Long: 3 Months or more
Significance:
Major or Minor, rated from 1-10
Colorado in 2014 (MAJOR) -- 10
Nevada in 2016 (Minor) -- 4
Directness Quotient:
Direct Catalyst
The event itself acts as a direct catalyst, such as Colorado recreational sales on 1/1/14
Indirect Catalyst (Discussion catalyst)
Most catalysts possess more than just an event-based component.
Many times the discussion and media attention surrounding a catalytic event (can be positive or negative) and the associated emotions attached to it also acts as a catalyst itself.
The Spicer and Sessions comments initially acted as a direct catalyst, but they also led to an ongoing discussion in the media about the future possibility of a federal crackdown on marijuana.
That negative possibility caused prolonged fear, which caused a sustained sector selloff.
The lengthy period of discussion that followed the Spicer/Sessions comments and the associated investor sentiment that arose as a result are hallmarks of an indirect catalyst.
Most direct catalysts cause some type of discussion that can have a prolonged effect – it is usually just a matter of degree.
I like to think of a direct catalyst having an immediate effect and the discussion surrounding it (the indirect aspect) dictating the significance and duration of the catalyst as a whole.
The example above describes the direct and indirect nature of a negative catalyst – of course, a positive catalyst and its resultant discussion can lead to a sustained sector rally as well.
SUPERCATALYSTS
These are the biggest catalysts of all, the real gamechangers.
There are only two remaining:
Rescheduling of cannabis (de facto federal medical marijuana legalization)
Federal legalization of recreational cannabis
THE 2018 CATALYSTS
JANUARY 2018
California will begin sales of recreational marijuana on the first day of the new year
Amplitude:
Positive
Duration:
Long
Significance:
Major – 9
Direct Catalyst:
California is the biggest state in the union and the 6th largest economy in the world
California’s native population is 40M and annual tourists number 270M
Even just with medical sales only, they currently generate the most cannabis revenue of any state at $2 Billion
California marijuana revenue expected to grow to $5 Billion next year, taking national sales from $7B in 2017 to $10B in 2018
We’ve recently seen the Canadian pot stocks enter a mania, in part due to upcoming adult use legalization in July 2018, and California’s cannabis market is even larger
Indirect Catalyst:
Loudly signals the marijuana revolution is too strong to stop now
Huge momentum booster to kick off the new year after a dreadful 2017
Blatantly exposes the raw hypocrisy of the largest state in the union selling a federally illegal substance
The media is going to have a field day with this hypocrisy
Expect to see editorials in major newspapers around the country supporting a rescheduling of marijuana
Bigtime national media coverage on television, radio, internet, social media, blogs, forums will further the discussion and debate around rescheduling
International media coverage
Banking solutions should move to the forefront of discussion as well
Increases pressure on Congress to move cannabis to Schedule II
JANUARY/FEBRUARY 2018
Vermont legalizes recreational marijuana via legislature
Amplitude:
Positive
Duration:
Short
Significance:
Minor -- 2
Direct Catalyst:
First non-ballot recreational cannabis legalization bill gets signed into law
This bill is for non-commercial legalization, so it permits home grows and possession but not storefronts
The bill permitting commercial cultivation, production and dispensaries is likely to pass in 2nd half of the year
Indirect Catalyst:
Any historical event generates media attention and discussion
Always most difficult to be the first to do something new or different
Breaks down barriers and paves the way for other east coast states -- New Jersey, Delaware, Connecticut, Rhode Island -- to follow suit in 2018
MARCH/APRIL/MAY 2018
New Jersey legalizes recreational marijuana via legislature within first 100 days of Governor Phil Murphy’s tenure
Amplitude:
Positive
Duration:
Long
Significance:
MAJOR with a capital MJ -- 9
Direct:
Unless Delaware beats it to the punch, New Jersey would become the first state to pass commercial recreational legalization of cannabis through the legislature.
Cultivation, production and dispensary licenses are included in bill
Indirect:
Proves that Massachusetts was no fluke, now two bigtime northeast states are full-on legal
New Jersey would handily become the 2nd largest state by population to legalize adult use MJ
Has great potential to trigger a state legislative tsunami of recreational cannabis in 2018 as Rhode Island, Connecticut, and Delaware follow suit -- all three could legalize by year end, with Delaware being the favorite to be next
New Jersey and New York are attached at the hip and the discussion around recreational legalization in New York’s legislature will increase significantly (though I don’t expect NY to pass recreational until 2019)
The close geographic proximity to the financial epicenter of America will attract serious money interested in investing in New Jersey MJ
The population density of the NY/NJ metropolitan area is massive and citizens from surrounding states (New York, Connecticut, Pennsylvania) would make the size of the NJ cannabis market absolutely enormous – this also incentivizes those neighboring states to get their asses in gear on legislation lest they lose out on tax money to Jersey cannabis
Takes the baton from California and intensifies the drumbeat of pressure on Congress to reschedule cannabis
MAY/JUNE/JULY 2018
Epidiolex (cannabis-derived CBD) receives FDA Approval
Amplitude:
Positive
Duration:
Long
Significance:
MAJOR – 9.5
Direct:
GW Pharma’s epilepsy drug has the experimental data required to support its approval
Would become the first actual cannabis-formulated medication to receive FDA approval
Essentially 100% cannabis-derived cannabidiol (CBD), which is currently Schedule I
FDA indication for Lennox-Gastaut and Dravet Syndrome
Application submitted on 10/30/17
Indirect:
If FDA approves Epidiolex, by law the FDA/DEA will have 90 days to reschedule it.
GW Pharma is requesting Schedule IV so that is likely what will happen.
The approval and rescheduling of cannabis-derived CBD means that for the first time the federal government is admitting that CBD has medical value.
Because there are three different synthetic THC drugs that are currently FDA approved (Marinol, Syndros, Cesamet), the government has already basically admitted that THC has medical value.
Logic would follow that if CBD and THC admittedly have therapeutic value, how can the cannabis plant remain on Schedule I?
We already know that logic doesn’t motivate the FDA and DEA when it comes to the issue of rescheduling cannabis – the former is controlled by big pharma and the latter is law enforcement, two parties that stand to be hurt financially if cannabis was rescheduled.
So I don’t expect the FDA or DEA to reschedule cannabis.
However, what I do anticipate happening is that the gargantuan hypocrisy of the situation will lead to the generation of enormous media attention and public pressure to reschedule cannabis.
The public pressure will be transmitted into political pressure on Congress to reschedule cannabis as a Schedule II substance.
If Congress has not already rescheduled cannabis before Epidiolex attains FDA approval, or before Epidiolex (CBD) is rescheduled, then I anticipate that Congress will reschedule cannabis within 1-3 months of Epidiolex’s (CBD) rescheduling, most likely in the late summer or early fall.
The bottom line is the minute Epidiolex (CBD) receives FDA approval, the media attention and discussion revolving around cannabis’ imminent rescheduling will be the biggest single catalyst to hit the sector since Colorado began sales of recreational marijuana in January 2014.
So months before cannabis is actually rescheduled by Congress, the discussion around this topic will serve as an indirect catalyst to light up the MJ sector.
JULY 2018
Canada legalizes recreational marijuana and begins sales
Amplitude:
Positive
Duration:
Medium
Significance:
Major – 7
Direct:
Federal legalization of recreational cannabis in Canada is a harbinger of what’s to come for America in the next 24-36 months
Lays out a roadmap for federal legalization of medical and recreational cannabis in America
Normalizes adult use cannabis to those in government and society who still require convincing
Indirect:
If Congress has not yet rescheduled marijuana, the pressure on them to do so will continue to increase
Canada makes America’s perspective on the issue of cannabis look very antiquated
Establishes a blueprint that America can use for eventual federal legalization of recreational cannabis in 2020-2021
JULY 2018
Massachusetts begins sales of recreational marijuana
Amplitude:
Positive
Duration:
Long
Significance:
Major – 7
Direct:
The first northeast state to sell recreational marijuana in dispensaries will be a huge news story on the east coast.
Allows nearby states with legalized medical marijuana to observe firsthand that adult use cannabis sales will not destroy society via reefer madness.
Indirect:
Encourages NY, CT, RI, PA to hop on board the adult use MJ bandwagon
Until another northeast state starts selling recreational cannabis in dispensaries, Boston may become the Denver of the northeast as people from nearby states travel to purchase cannabis
Makes the tax revenue argument for adult use legalization more effective
AUGUST/SEPTEMBER/OCTOBER 2018
Congress Reschedules Cannabis as a Schedule II Drug
Amplitude:
POSITIVE
Duration:
Long
Significance:
MAJOR – 10 – This is a SUPERCATALYST
Direct:
The cumulative pressure from the biggest state in the union and the first northeast metropolis state starting sales of recreational marijuana (CA and MA, respectively), the first state in America to pass commercial recreational marijuana through the legislature (NJ) and the FDA approval of cannabis-derived CBD (Epidiolex), all occurring within the first half of 2018, ratchets up the political pressure for Congress to finally face the music and solve the hypocrisy of fraudulently maintaining cannabis as a Schedule I Drug.
The vote isn’t even close.
De facto federal legalization of medical marijuana.
Indirect:
This is the single most important event in the history of cannabis in America.
If you missed out on 2014’s Mania, you will have another chance to experience what the most extreme stage in the MJ Sector Mania Cycle feels like.
This is MANIC MANIA.
Enjoy it.
This is one of only 2 remaining SUPERCATALYSTS in the MJ sector, with the last one being federal legalization (There were three, but Colorado starting recreational sales on 1/1/14 was the first)
The number of ramifications is astounding and I can’t possibly cover them all, so I will touch on some of the most important.
Rescheduling cannabis as a Schedule II Drug will pave the way for banking to open up, as cannabis will no longer be considered federally illegal.
This is great for the industry itself, as now companies won’t have to stash hoards of cash in safes any longer.
It will also change the game in terms of access to capital.
Banks and other financial institutions will now be able to loan money to aid the growth of the industry.
Investment capital will flood the sector, as cannabis now becomes “safe” with the chance of any significant federal interference now extinguished
If there ever was a green light for an industry this is it.
Marijuana stocks will go vertical and it will feel like 2014 again.
Many will shift focus to not if, but when marijuana stocks will be allowed to uplist to Nasdaq – my guess is somewhere between June-September 2019
And now that medical marijuana is no longer federally illegal, the industry will naturally begin talking about the final SUPERCATALYST – federal legalization of recreational marijuana, the granddaddy of discussion catalysts.
NOVEMBER 2018
Michigan, Ohio and possibly Arizona on ballot for recreational marijuana
Amplitude:
Positive
Duration:
Short
Significance:
Major – 6
Direct:
Michigan and Ohio pass recreational legalization by the people
If Arizona gathers enough signatures in time, it will pass there as well
Indirect:
This would ordinarily be a pretty big deal, since the Midwest is currently a recreational cannabis desert, and in a single election, two pretty large states would put an end to that.
But everything is about timing.
And everything is relative.
After rescheduling, most catalysts will likely seem a lot less exciting than they may look on paper.
If cannabis has not been rescheduled by Congress before the elections, and Democrats win a congressional majority, then rescheduling is likely to happen quickly – so that would certainly increase the significance and strengthen the catalyst of the 2018 elections apart from MI/OH/AZ
Miscellaneous catalysts:
Delaware, Connecticut, Rhode Island and Vermont could all legalize recreational marijuana via legislature at different times throughout the year, though I expect the majority to take place in the 2nd half.
As single catalysts, none of them can compare to New Jersey, though I think Delaware is pretty significant because of the proximity to Washington DC, and Connecticut is important because it borders New York -- and if neighboring New Jersey and Connecticut pass recreational marijuana via legislature in 2018, the discussion of New York joining the gang will be pretty loud.
THE UNIQUENESS OF THE 2018 MARIJUANA MANIA
The marijuana sector is clearly a catalyst driven sector.
We have seen two manias thus far and both were triggered by only a single catalyst (Colorado becoming the first state to sell recreational marijuana in 2014 and CA/MA/NV/AZ/ME on the ballot for recreational marijuana in 2016)
Both manias lasted only 2-3 months and ended due to the occurrence of a negative catalyst (SEC halts and Trump/Sessions/Christie), coupled with the fact that there wasn’t a second positive catalyst in the near future to counterbalance the negative catalyst.
2018 is a calendar year that is full of potential major catalysts.
Real gamechangers.
And the first SUPERCATALYST since January 2014.
California selling recreational marijuana.
New Jersey passing recreational marijuana through its legislature.
Epidiolex (CBD) receiving FDA approval.
Cannabis being rescheduled by Congress.
That is really a GRAND SLAM of catalysts.
And in addition, Canada will legalize recreational marijuana and begin sales, Massachusetts will begin recreational sales, and Michigan/Ohio will become the first Midwest states to legalize the plant for adult use. And Delaware, Connecticut and Rhode Island may join the gang via legislature.
So the number of bigtime catalysts makes 2018 a completely different ballgame than 2014 or 2016.
The significant catalysts are also spread out throughout the calendar year.
Broken down into quarters, California is Q1, New Jersey is Q2, Epidiolex approval and CBD rescheduling is Q2/Q3, Massachusetts is Q3, Canada is Q3, Congress rescheduling cannabis is Q3/Q4, Michigan/Ohio/Arizona is Q4.
And remember, the date of the catalyst is not the start date of the catalyst’s effect on the marijuana sector. Discussion and media coverage surrounding catalysts typically becomes louder 1-2 months beforehand and stays louder for several months afterwards.
Indirect (discussion/media attention) effects should cause a continual stream of positive sentiment from January through December.
It really does seem like we have a very legitimate chance for an entire year of mania in the MJ sector.
Now that doesn’t mean there won’t be periods where the sector isn’t completely on fire.
But the most likely scenario is that when the sector isn’t outright manic, it remains at least warm (similar to February 2017 before the Sessions/Spicer comments) throughout the year.
Another ramification of the multiplicity of significant catalysts is that if there is some negative disturbance in the MJ Sector, there are near-term additional positive catalysts to counterbalance its effects, so it is unlikely that any single negative catalyst can shutdown the mania. The marijuana sector in 2018 is much more bear-proof than in prior manias, even in the event of a negative catalyst.
The most sound argument against the hypothesis that 2018 will be a yearlong mania is that some of the important catalysts don’t actually materialize.
Or that some don’t happen on the timetable as outlined above.
These are all only potential catalysts and some of them are more likely to occur than others.
That’s something we will just have to wait and see about…
So what about the pink elephant in the room?
Can Jeff Sessions and the Department of Justice rain on our marijuana mania?
I suppose it is theoretically possible.
Is it likely to occur?
Not according to the evidence we have collected throughout the year.
In March, Sessions talked tough about potentially cracking down on marijuana, saying it was only “a slightly less awful life-wrecking dependency than heroin.”
But that was March, shortly after his appointment to Attorney General.
In the interim, he commissioned a task force -- replete with career prosecutors and law enforcement officials -- to let him know his feasible options with respect to federally cracking down on marijuana.
And according to the Associated Press who read through the report, the surprising recommendation of the council was to continue following the Cole Memo.
It’s been nearly 10 months since Sessions was sworn in and his DOJ has not interfered with any states this year.
Why would they start now?
Political pressure is certainly moving in the wrong direction, as the latest Gallup Poll clearly shows – 64% of Americans are pro-legalization, including 51% of Republicans (up a whopping 9 points since 2016).
Over 70% polled say to leave the states alone.
Medical Marijuana has a 94% approval rating, according to Quinnipiac’s latest poll.
94% of Americans agreeing on any issue is really rare.
And the biggest state in the union is about to start sales of recreational marijuana in about two weeks.
It certainly seems a little late in the game to interfere with states’ rights.
I do expect the DOJ to declare their official policy on cannabis enforcement pretty soon, and it might be a bit more stringent than the Cole memo, but any significant state interference would have to be considered relatively unlikely at this point.
But anything is possible – aside from Willie Nelson and Snoop Dogg giving up marijuana and joining the DEA -- so we will just have to wait and see.
GRAND SALAMI STOCK PICKING METHODOLOGY
THE 2016 ELECTION GRAND SALAMI METHODOLOGY – MCOA, AMMJ, CNAB
Reverse Engineering the 2014 MJ MANIA
With the seemingly gigantic catalyst represented by the November 2016 elections looming ahead and its probabilistic concomitant mania, in the Spring of 2016 I embarked upon a comprehensive analysis of the 2014 MJ Mania. Since history tends to repeat itself, I sought to reverse engineer the 2014 MJ mania to determine which specific factors possessed the greatest predictive capacity for identifying the stocks with the highest probability of delivering outsized returns -- I wanted to develop a comprehensive blueprint and subsequently pinpoint which components of the model would lead to the highest % gains for my MJ portfolio in the fall.
After approximately 500 hours, the deconstruction of the mechanistics of the 2014 MJ Mania into its component parts was completed. Relying somewhat on my firsthand experience deconstructing the late 1990’s Nasdaq internet sector mania -- you can read about it here -- http://investorshub.advfn.com/boards/read_msg.aspx?message_id=136784484 -- and much more strongly on my graduate school training in the methodology of instrument construction, I reviewed each and every MJ stock and divided about 350 stocks into 4 quartiles by performance as judged by % gain from trough to peak.
I removed the stocks in the middle quartiles so I was left with the top performing quartile and the bottom performing quartile.
Then I performed a series of statistical analyses including discriminant function analysis and factor analysis, along with a variety of other statistical methodologies and mathematical simulations.
Strongly resembling my primordial findings from 1998, the final product was a factor-based algorithm whose composition was very heavily weighted towards measures of sentiment. Supply/Demand factors were the second most important construct. Technical factors were significantly lower weighted. And not surprisingly, similar to the internet sector mania, traditional fundamental factors (revenue, revenue growth, profit margins) and valuation metrics (P/E ratio, market capitalization) possessed no predictive value.
From the lowest priced shares purchased to the peak price in November:
MCOA gained 5600% -- from .0035 to .1985
AMMJ gained 2370% -- from .085 to 2.10
CNAB gained 2040% -- from .1565 to 3.35
THE 2018 GRAND SALAMI METHODOLOGY
Reverse Engineering the 2014 & 2016 MJ MANIA
I performed the same analysis once again, this time on both MJ manias
SALAMI factors were extracted directly from the statistical analysis of the 2014 and 2016 MJ Manias -- those are the factors that possess predictive value for stock performance by % gain inside of both manias
Utilizing a weighted scoring system, a preliminary SALAMI score is calculated for every MJ stock
IPA THEORY is an outgrowth of my intensive study of the sentiment-based SALAMI factors -- it is my attempt to break down sentiment into its essential constituents... you can read more about it here: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=136788597
All MJ stocks with a preliminary SALAMI score greater than the 75th percentile are assigned scores for the IPA subfactors, which together comprise the IPA score
The final SALAMI score is a composite measure consisting of the preliminary SALAMI score and the IPA score
Only the MJ stocks that score at or above the 90th percentile for the final SALAMI score meet criteria to be potentially selected for entrance into THE GRAND SALAMI
The 2018 GRAND SALAMI selections are made based on a combination of the final SALAMI score and my personal judgment
In the end, I believe the collaboration amongst statistical formulation, mathematical computation and human analysis provides the very best results
THE SUBSECTOR SUPERMANIA
The key to the biggest returns during a MJ MANIA
When reviewing the stocks ranked by % gain from highest to lowest in THE 2014 MJ MANIA, it became apparent that stocks in the same subsector did not trade independently of one another, but instead tended to trade in specific clustering patterns stratified by performance. The mania was so strong in 2014 that nearly every marijuana stock achieved tremendous gains; however, it was readily apparent that certain subsectors vastly outperformed others. Vaporizer stocks generally experienced superior returns, in comparison to other subsectors such as lighting, security and financing. Stocks whose primary business plan revolved around vaporizers, along with stocks who merely announced they were entering the vaporizer industry became absolute rockstar Kangaroos hopped up on Adderall. Everybody who witnessed the unfolding of the mania remembers the singular posterchild encapsulating the utter ridiculousness of it all as the vaporizer play SPLI meteorically rose 75000% in 10 weeks.
The utter dominance of the vaporizer subsector during the 2014 MJ Mania calls out for a new term: SUPERMANIA.
Although stocks residing in the Supermania subsector generally possess the greatest potential to experience the rarefied air of 99th percentile returns, the clustering of stocks within a given subsector by performance was not so clean and absolute that every single vaporizer stock achieved the most superior returns. Many of them did not.
Only the very best of breed stocks within the vaporizer Supermania vastly outperformed nearly every other stock in the MJ universe to achieve Superman-like returns.
We saw a similar phenomenon during the 2016 MJ Mania where the best performing subsector this time around was the all-purpose cannabis stocks. There were more than a dozen of them and as a subsector they handily outperformed the MJ sector as a whole.
But only the top stocks in that subsector – MCOA, AMMJ, and CNAB -- participated in the SUPERMANIA.
In early 2017, a SUPERMANIA in cannabinoid pharmaceutical stocks occurred, and once again only the very best of breed stocks in that subsector participated in it -- OWCP and CNBX.
So it seems the key to picking the very best stocks in the 2018 MJ MANIA will be to first predict which subsector will experience the SUPERMANIA, followed by identifying the best of breed stocks in that subsector.
Best of luck to everybody in the 2018 MJ MANIA,
Sleek
Any news on new marijuana stocks or good plays?
Check out a real medical marijuana company acbff, look at their news and chart then Google the news about them. I predict 10 dollars in the next year or a little after. Another is xxii stock.
KGKG CBD WATER LINK FACEBOOK INSTAGRAM TWITTER
https://www.instagram.com/highdrateme/
https://m.facebook.com/HighDrateMe/
https://mobile.twitter.com/highdrateme
United States Cannabis Coalition
THE UNITED STATES CANNABIS COALITION (USCC) IS A PRO-CANNABIS NON-PROFIT ORGANIZATION DEDICATED TO INFLUENCING FEDERAL LEVEL DECISION MAKERS SO THEY HONOR STATE’S RIGHTS AND STATE MANDATED MARIJUANA LAWS AS WELL AS REFORM OUR ANTIQUATED AND FAILED FEDERAL DRUG LAWS.
During the campaign, President Trump pledged that as President he would honor and protect state’s rights in the 29 states that have legalized cannabis. Candidate Trump went so far as to say that if a state approved the use of cannabis for medicinal purposes he supported that decision.
The Obama administration wisely decided to suspend enforcement of federal law prohibiting cannabis possession in the 29 states where voters have approved it. Now, however, despite President Trumps pledge, Trump Attorney General Jeff Sessions and Homeland Security Secretary John Kelly have announced a crackdown in the 29 states that have legalized cannabis and a resumption of federal law enforcement regarding possession and distribution of cannabis.
The US Cannabis Coalition is a coalition of Republicans and Democrats, Liberals, Conservatives, Libertarians, and others, who support the decision of the states to legalize cannabis. It is our intention to identify, reach, and mobilize, millions of pro-cannabis voters to tell the President to keep his word. It is our intention to lobby the Trump Administration from the top on down to recognize the medicinal value and potential of cannabis.
The facts are on our side-opioid addiction is down in the states that have legalized cannabis as are drug overdose deaths and all classes of petty non-violent crime. At the same time, we must increase public awareness of the millions in state revenues state-approved cannabis is generating for the states and the thousands of jobs this state-approved multi-billion cannabis industry has created. Legalized cannabis has also crippled the drug cartels who extort those who are sick or dying.
Millions of Americans are getting medical relief from the use of cannabis in all its forms. When Attorney General Jeff Sessions says “good people don’t smoke marijuana” he’s wrong; sick people smoke marijuana, many millions of them.
The USCC will work to persuade President Trump to keep his pledge to protect state legalized cannabis.
The USCC is also dedicated to persuading the President to reclassify cannabis from its current Schedule 1 classification under federal law (where it is grouped with heroin and other far more dangerous drugs) so that doctors across the country can legally prescribe it for patients who could benefit and banks could conduct legal cannabis business.
The USCC also supports additional federal funding for unbiased research into the medicinal benefits and properties of cannabis. Extensive and well-funded research in Israel indicates the potential for medical breakthroughs and better research in the United States is vital.
USCC will also continue to build a coalition of liberal Democrats and libertarian Republicans in the US House and Senate to spearhead an eventual effort to introduce and pass a bill legalizing the possession and use of cannabis through legislation in the event that the Trump administration does not reverse it current plans to override the decision of 29 states to legalize cannabis use and crack down on cannabis obsession and distribution.
Make no mistake about it, the well-heeled special interests of Big-Pharma will actively oppose our efforts to reform federal cannabis law as will the “drug warriors” in the Trump Administration who are ignoring the President’s pledge. That’s why we need you to support and contribute to the United States Cannabis Coalition today.
Subscribe for updates today.
http://uscannabiscoalition.org/
AMFE GROZONE on radio
amfils grozone devisional ceo will be on ksco radio to talk about hydroponics and the pesticide issue and roto-gro deals
AMFE UPDATE+RADIO!!
RADIO REMINDER! $AMFE$
http://ksco.com/schedule
KSCO WITH WES will be hosting my two cents AMFE 6-7pm pacific time California time..TODAY 5/28/17
AMFIL TECH PR ON OTCMARKETS RECAP OF LAST 6 MONTHS
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=131710981
CANNAINVESTOR Magazine MAR/APR 2017 Issue
https://www.joomag.com/magazine/cannainvestor-magazine-march-april-2017/0477830001490386915?token=xBd7xtAGSSqOjuMAXE079A%2Fw3%2FmkR5Fqgm%2Ba0L6z9ZDd%2BDT3LMqmIszpuCMeUrdT9hjHq8Gk5I3qkzLHi8t7iKpofMyoFf0UAmu%2BF3RhX%2B13UvzLk%2F1X%2FjnuJvXYWgxOeZiP%2FT7NRLJQitP%2BficvR%2FRM6Le9rnPaYvWNVwasbkYzQnwT07uDKW%2Bv4ImOjZAE0dfCs%2Bl%2B70G9v%2FTA92n3UA%3D%3D&ref=email
See this pr on NDEV .325 and see why it may be one of the best MJ plays available:
Novus Initiates Medical Cannabis Worker's Comp Package
Accesswire AccesswireNovember 2, 2016
Recreational Users Will Become Medical Users
MIAMI, FL / ACCESSWIRE / November 2, 2016 / Novus Acquisition and Development, Corp. (OTC Markets: NDEV), the nation's first healthcare insurance carrier/aggregator in the medical cannabis sector demonstrates how their MedPlan will capture market share of recreational users and convert them to medical users in California.
With the impending approval of Proposition 64 in California, Novus has put into operation, through their insurance subsidiary WCIG Insurance Services, Inc., a supplemental Workers Compensation Program that will include medical marijuana for patients in the State of California.
How the MedPlan was derived was based on the Workers' Compensation Insurance Rating Bureau's Actuarial assessment, that workers' compensation premiums in California continue to grow at double-digit rates. The state's workers' comp written premium accounts for more than a quarter of the U.S. total, but only 12 percent of America's workforce, according to the report. Additionally, to make matters worse, the California coverage compares poorly with the rest of the nation
How does California's workers' comp and Novus' supplemental medical marijuana insurance coverage benefit patient and employers interests? Four principal factors: a) California has the highest permanent disability claims in the nation with an inherent on going pain management crisis, b) the state has among the highest claims in terms of medical costs, c) it has a high cost of delivering insurance benefits and; d) another driver of California's higher premiums is the state's medical treatment costs.
How we approached solving the problem is by implementing a supplemental workers compensation program with Novus' infrastructure with California marijuana dispensaries. Then instrumentally delivering a supplemental worker's compensation plan will ease insurers and employers burdens by allowing Novus to procure, in network, a consortia of physicians that will take in patients, generate more medical marijuana recommendations for the protocol for pain management and other aliments to ease suffering. What makes this of value for insurers and employers is that California worker's compensation premiums will decrease losses because medical marijuana and Novus premiums are affordable.
Once the ballot initiatives in California is approved under Proposition 64 Novus will take advantage of three areas a) the abatement of taxation for medical marijuana cardholders b) many doctors are approving medical cannabis and writing recommendation forms for patients because of, c) the opioids crisis, many California doctors are writing less prescriptions for opioids and combining it with medical cannabis for pain management. The end result will be that Novus will get an increase in patient/member signups from the overlapping of recreational users that become medical users under this program.
The graphic below shows the percentile range and the overlying of cannabis users in medical (33%) versus recreation (55%) users, coinciding with worker's comp claims, which is estimated at 12%.
NDEV 2nd Quarter Financial Filing: http://bit.ly/2cJ3Efj
About Novus
Novus Acquisition & Development Corp. (NDEV), through its subsidiary WCIG Insurance, provides health insurance and related insurance solutions within the wellness and medical marijuana industries in states where legal programs exist. Novus has positioned itself to gain market share within many lines of insurance business within and outside of the MMJ sector.
Novus will work as outside developers and will not cultivate, handle, transport grow, extract, dispense, put up for sale, put on the market, vend, deliver, supply, circulate, or trade cannabis or any substances that violate the United States law or the Controlled Substances Act, nor does it intend to do so in the future and will continue to follow state and federal laws. The statements made about specific products have not been evaluated by the United States Food and Drug Administration (FDA) and are not intended to diagnose, treat, cure or prevent disease. All information provided on these press releases or any information contained on or in any product label or packaging is for informational purposes only and is not intended as a substitute for advice from your physician or other health care professional. Once a push notification is competed the transaction is solely between the state-licensed dispensary and the registered patient.
The state laws are in conflict with the federal Controlled Substances Act. The current administration has effectively stated that it is not an efficient use of resources to direct federal law enforcement agencies to prosecute those lawfully abiding by state designated laws, allowing the use and distribution of medical marijuana. However, there is no guarantee that the current administration, nor any future administration, will not change this policy and decide to enforce the federal laws strongly. Any such change in the federal government's enforcement of current federal laws could cause significant financial changes to Novus Medical Group. While we do not intend to harvest, distribute or sell cannabis or cannabis related products, we may be harmed by a change in enforcement by federal or state governments.
For more information, check out: http://www.getnovusnow.com
For NDEV 2nd Quarter Financial Filing: http://bit.ly/2cJ3Efj
Learn How Insurance Companies Are Evaluated: http://bit.ly/2ddIYva
Forward-Looking Statements
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, includes codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. Novus Medical Group disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact Information
Corporate:
Chairman and CEO
Frank Labrozzi
frank@ndev.biz
855-228-7355
Investors:
Hayden IR
hart@haydenir.com
917-658-7878
SOURCE: Novus Acquisition and Development, Corp.
Though still relatively unknown in the MJ sector, it is definitely gaining attention deservedly so all imho...tuna
VMNT mj industry + revenue + multiple cbd products http://www.otcmarkets.com/stock/VMNT/financials#
Add $ICC in the list...
http://web.tmxmoney.com/article.php?newsid=5805900313936207&qm_symbol=ICC
$ACOL$
10-Q out, also news of possible Marijuana packaging contract with Canada for their Medtainer. (Medical grade grinder/ container *CHILD-PROOF* is the key)
Chart has been climbing with no signs of slowing down. Pennies coming soon.
$LAG.C News - Laguna's CBD Cannaceuticals Licence Expanded to 4 Countries http://tsxpennystocks.ca/miscellaneous/2016-news/164-laguna-s-cbd-cannaceuticals-licence-expanded-to-4-countries
$LAG.V Laguna Blends Signs NFL Champion Marvin Washington
http://www.celebstoner.com/sports/sporting-highs/2014/10/15/former-nfl-star-says-players-need-medical-marijuana/
$SRNA Refer to 2014 Green rush and 1849 Pick 'n Shovel Gold rush California ;) .. it's just my opinion, but with the right Company moves SRNA will be many dollars... the wagons are heading out and the equipment to mine will be needed.
TURV ACAN GRNH EDXC HSCC MCIG
$ACG.C - Alliance Growers, WFS Pharmagreen to Develop Cannabis Facility
http://www.stockwatch.com/News/Item.aspx?bid=Z-C%3aACG-2399757&symbol=ACG®ion=C
4/20 Is Here: These Are The 15 Most Traded Weed Stocks
8:13 am ET April 20, 2016 (Benzinga) Hot Stories Print
Unfortunately, until marijuana is legalized in the United States on a federal level, the vast majority of marijuana stocks will likely continue to trade over-the-counter and continue to be horrible long-term investments. Aside from GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH), which trades on the NASDAQ, no other weed stocks trade on major U.S. exchanges.
Trading on the OTC market means that many of these stocks have relatively light regulatory oversight and little or no institutional backing. For now, these stocks have been serving mostly as day trading instruments.
Short sellers have been particularly profitable. All 15 of Benzinga’s “15 Marijuana Stocks To Watch In 2015” finished the year down at least 30 percent. If you take GW out of the mix, 12 of the remaining 14 stocks were down at least 72 percent.
Related Link: 15 Marijuana Stocks To Watch In 2015: Where Are They Now?
Until the marijuana industry becomes more mainstream, decent long-term investments will be hard to come by. But if you’re looking to trade weed stocks in the meantime, at least you can avoid the most illiquid stocks.
StockStat has a full list of marijuana stocks that you can sort by trading volume. However, it’s important to remember that 2 million in trading volume may seem impressive, but for a stock that trades at $0.0001 per share, it only amounts to $2,000 in liquidity.
Top 15
With that in mind, here are the 15 weed stocks with the highest daily trading volume, according to StockStat:
Bayport International Holdings Inc (OTC: BAYP)
Greengro Technologies Inc (OTC: GRNH)
Dewmar International BMC Inc (OTC: DEWM)
Terra Tech Corp (OTC: TRTC)
VAPE HLDGS INC COM (OTC: VAPE)
American Green Inc (OTC: ERBB)
Cannabis Science Inc (OTC: CBIS)
Medical Marijuana Inc (OTC: MJNA)
EFFTEC INTL INC COM (OTC: EFFI)
Vapor Group Inc (OTC: VPOR)
Hemp Inc (OTC: HEMP)
Growlife Inc (OTC: PHOT)
Fastfunds Financial Corporation (OTC: FFFC)
Latteno Food Corp (OTC: LATF)
Easton Pharmaceuticals Inc (OTC: EAPH)
Disclosure: The author holds no position in the stocks mentioned.
© 2016 Benzinga.com.
Looking for medical marijuana at a low price.... to increase the work efficiency.
AFAI- Plans to have 4 to 6 Kaya Shack Cash Cows in Oregon. Market Cap IMO will take care of itself. With recreational revenues will grow exponentially quarter after quarter.
Finally a pot stock that sells weed!!!!!!!!!!!!!!!!!!!!
Here is some dd.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=107719533
AFAI AFAI AFAI Oregon pot play.
They actually sell pot out of a brand name store front. Kaya Shacks.
One store, publicly traded stock, and sell pot to retail.
Expanding phase going on.
Low float under 5Billion, LOL, debt under control,
High Market cap is the only concern.
It shows killer inter day dips with recovery. It's a great stock to be watching. .14 seems to be the price it wants to remain at. I want in under a dime, but damn! Either it's paint job city EOD or someone knows more than me.
And I don't smoke dope.... Or drinking myself to death after age 40.
Qasp had yet another 700% run.
Back down in reload range. I may take one last ride, but losing confidence in the CEOs ability. I see no clear direction, toxic debt has taken over, no follow through on either story fronts and massive O/S.
Holding so many free shares its hard to give up. I'm rebuying the 2s.
It's s sickness.
PMBS a MMJ Leader $$$$$$$$$$$$$$$$$
a Incredible Buy $$$$$$$
http://www.puramedbioscience.com/
QASP up 25% on good volume
bid jumped up a tick and signals turn around.
News is flowing.
Easy multi bagger as the business plan comes together.
It's even being weakly copied in GSDM.
Crazy low market cap of $2mm
Compare to similar business ERBB with $70mm
Insane numbers and potential.
$ALGA begins hemp production!!!
ALGA Begins Production of Hemp in the State of Vermont
(NEW YORK)--Algae International Group, Inc. (OTC:ALGA), through its operating subsidiary American Seed & Oil Company, Inc., is embarking on the production of hemp as feedstock for its pending hemp oil business.
Hemp Production in Vermont
The Company has already begun the process on hemp production in the state of Vermont to grow hemp for feedstock for their future hemp oil business. According to their website, the Company has already contracted hemp growers within the state of Vermont, and that planting for this crop has already been completed.
The hemp that will be produced will be developed as a feedstock for the production of hemp oil for the commercial market, and will also explore a number of other cannabis related consumer health products as well.
In June 2014, Vermont signed into law a bill that legalizes the cultivation of cannabis sativa, a relative of marijuana that proponents say could be a lucrative value-added crop for Vermont farmers.
ALGA is a relatively new player in the active sector, but with such a low float, and hemp production already moving ahead, ALGA could draw in traders interested in the marijuana sector and place this deal on some new radars. ALGA was last traded at a price of $0.20 per share.
http://www.wallstreetnewscast.com/profile/alga.html
RAMO spreading the news here~ Med CBD Buis is big money, the extraction process is critical and RAMO has it..... With Small SS here, the pps will fly once the herds get the word..
About RAMO Bio-Med, Inc.
RAMO Bio-Med, Inc. is a wholly owned subsidiary of Ramoil Management, Ltd. (RAMO) and is a development stage company. The Company is the operating company of the newly acquired Supercritical CO2 Molecular Extraction Technology and will be building operating production facilities and research labs, both domestically and internationally, focused on its own proprietary strain of High CBD Extremely Low THC Charlottes Webb and Extraction Facilities (Labs and Manufacturing), for the development, production and sales of CBD extractions, concentrates and medicines.
Finally confirmation UNGS Moving UP
gwinis Wednesday, 09/03/14 11:47:39 AM
Re: zoriden post# 44784
Post # of 44858
Artemis is the development and production arm of the MJ dispensing unit. This operation is under the supervision and control of Sylios Corp. I understand that the members working with/for Artemis have a great deal of experience in vending services. My recommendation is to contact the IR department at Sylios:
info@sylios.com
Thank you for your inquiry,
Jim
James R. J. Scheltema, President
__________________________________________________________
Gwinis:
MUST READ...MMJ Brick n Mortar plays
ACGX (.003) vs REVI (.02)a great comparison of two printing/packaging companies entering into the Marijuana Sector.
REVI PPS (.022)
20M Market Cap
1M Revenue
950M O/S
2.5B A/S
Net income to common -499,000
REVI DD click
ACGX PPS (.003)
2M Market Cap
12M Revenue
688 O/S
750 A/S
Net Income to common +610,000
ACGX DD click
Which one do you think is "undervalued"? Folks if REVI is @ 02 and is 1/10th the company of ACGX........guess what
FFFC on Bottom and going to bounce good soon, look at 12 month chart when it was at bottom 3 months ago and popped up 48 clicks. Check out their websites and acquisitions. Solid play for 20+ bagger
QASP TIME TO ROCK. LOAD UP. 10 BAGGER HAPPENING!
UNGS-- Must look at... Two MJ companies acquisitions, Merger with Singifi Solutions (over 5 million in Rev's already), Name changes, all happening next week.
NEWS NEWS NEWSAug 07, 2014 (ACCESSWIRE via COMTEX) -- ST. PETERSBURG, FL / ACCESSWIRE / Sylios Corp (otc pink:UNGS),
The development of products utilized in the medical and recreational marijuana industry is pleased to announce that the Company's Board of Directors elected to form a new wholly owned subsidiary for its cannabis operations.
On July 2, 2014, the Company filed with the State of Florida to form Bud Bank, LLC. The Company received approval from the Florida Office of Financial Regulation for the use of the name Bud Bank for its dispensing product. Bud Bank, LLC will be dedicated solely to the Company's cannabis dispensing product. The Company will continue to seek products to acquire, license or develop through joint ventures through its cannabis subsidiary, The Greater Cannabis Company, LLC.
The Company's two websites will be live the week of August 11, 2014. Sales of the Company's new cannabis dispensing product will be initiated upon launch of its website.
Followers
|
29
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
381
|
Created
|
01/27/14
|
Type
|
Free
|
Moderator Alexulf | |||
Assistants seconway05 |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |